COVID-19 vaccine - Castlevax
Alternative Names: AVX/COVID-12 (Patria) Vaccine; AVX/COVID-12 vaccine; AVX/COVID-12-HEXAPRO; CVAX-01; Live Recombinant Newcastle Disease Virus Based AVX/COVID-12 Vaccine; NDV-HXP-S vaccine; Patria; Recombinant NDV Vectored Vaccine for SARS-CoV-2; Recombinant NDV Vectored Vaccine for SARS-CoV-2 - Avimex; Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2; Recombinant SARS-CoV-2 vaccine - Avimex; Sars-CoV-2 vaccine - AvimexLatest Information Update: 29 Aug 2024
At a glance
- Originator CastleVax
- Developer Avimex; CastleVax
- Class COVID-19 vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III COVID 2019 infections
Most Recent Events
- 29 Aug 2024 Phase-III clinical trials in COVID-2019 infections (Prevention) in Mexico (IM)
- 29 Aug 2024 Phase-III clinical trials in COVID-2019 infections (Prevention) in Thailand (IM)
- 29 Aug 2024 Castlevax plans a phase II trial for COVID-2019 infections (Prevention) in USA in Q4 of 2024 (Castlevax pipeline, August 2024)